Consequences of feedback in signal transduction for targeted therapies

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 770-775

  Klinger, Bertram ^a,b   Bluüthgen, Nils ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Drug response; Epidermal growth factor receptor (EGFR); Feedback; Mathematical modelling; Mitogen activated protein kinase (MAPK) signalling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR; VEMURAFENIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANAPHYLAXIS; BREAST CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONFERENCE PAPER; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; MELANOMA; NEGATIVE FEEDBACK; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; STOMACH CANCER; WILD TYPE; DRUG RESISTANCE; METABOLISM; NEOPLASMS; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, THEORETICAL; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84905862081     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140130     Document Type: Conference Paper

References (47)

1. Dhillon, A.S., Hagan, S., Rath, O. and Kolch, W. (2007) MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290
2. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A. et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339
3. Roberts, P.J. and Der, C.J. (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310
4. Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516
5. Kopetz, S., Desai, J., Chan, E. and Hecht, J.R. (2010) PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28 (Suppl.), 3534
6. Klinger, B., Sieber, A., Fritsche-Guenther, R., Witzel, F., Berry, L., Schumacher, D., Yan, Y., Durek, P., Merchant, M., Schäfer, R. et al. (2013) Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol. Syst. Biol. 9, 673
7. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A. and Bernards, R. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103
8. Friday, B.B., Yu, C., Dy, G.K., Smith, P.D., Wang, L., Thibodeau, S.N. and Adjei, A.A. (2008) BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68, 6145-6153
9. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70
10. Avraham, R. and Yarden, Y. (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12, 104-117
11. Cirit, M., Wang, C.-C. and Haugh, J.M. (2010) Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. J. Biol. Chem. 285, 36736-36744
12. Fritsche-Guenther, R., Witzel, F., Sieber, A., Herr, R., Schmidt, N., Braun, S., Brummer, T., Sers, C. and Blüthgen, N. (2011) Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Syst. Biol. 7, 489
13. Legewie, S., Herzel, H., Westerhoff, H.V. and Blüthgen, N. (2008) Recurrent design patterns in the feedback regulation of the mammalian signalling network. Mol. Syst. Biol. 4, 190
14. Blüthgen, N. (2010) Transcriptional feedbacks in mammalian signal transduction pathways facilitate rapid and reliable protein induction. Mol. Biosyst. 6, 1277
15. Patterson, K.I., Brummer, T., O'Brien, P.M. and Daly, R.J. (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 418, 475-489
16. Mason, J.M., Morrison, D.J., Basson, M.A. and Licht, J.D. (2006) Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol. 16, 45-54
17. Sturm, O.E., Orton, R., Grindlay, J., Birtwistle, M., Vyshemirsky, V., Gilbert, D., Calder, M., Pitt, A., Kholodenko, B. and Kolch, W. (2010) The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci. Signal. 3, ra90
18. Sauro, H.M. and Kholodenko, B.N. (2004) Quantitative analysis of signaling networks. Prog. Biophys. Mol. Biol. 86, 5-43
19. Yi, T.M., Huang, Y., Simon, M.I. and Doyle, J. (2000) Robust perfect adaptation in bacterial chemotaxis through integral feedback control. Proc. Natl. Acad. Sci. U.S.A. 97, 4649-4653
20. Muzzey, D., Gómez-Uribe, C.A., Mettetal, J.T. and van Oudenaarden, A. (2009) A systems-level analysis of perfect adaptation in yeast osmoregulation. Cell 138, 160-171
21. Kollmann, M., Lovdok, L., Bartholome, K., Timmer, J. and Sourjik, V. (2005) Design principles of a bacterial signalling network. Nature 438, 504-507
22. Cohen-Saidon, C., Cohen, A.A., Sigal, A., Liron, Y. and Alon, U. (2009) Dynamics and variability of ERK2 response to EGF in individual living cells. Mol. Cell 36, 885-893
23. Lefloch, R., Pouysségur, J. and Lenormand, P. (2008) Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol. Cell. Biol. 28, 511-527
24. Solit, D.B., Garraway, L.A., Pratilas, C.A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J.M., She, Y., Osman, I. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362
25. Yeh, T.C., Marsh, V., Bernat, B.A., Ballard, J., Colwell, H., Evans, R.J., Parry, J., Smith, D., Brandhuber, B.J., Gross, S. et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583
26. Dougherty, M.K., Müller, J., Ritt, D.A., Zhou, M., Zhou, X.Z., Copeland, T.D., Conrads, T.P., Veenstra, T.D., Lu, K.P. and Morrison, D.K. (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224
27. Brummer, T., Naegele, H., Reth, M. and Misawa, Y. (2003) Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22, 8823-8834
28. Schubbert, S., Shannon, K. and Bollag, G. (2007) Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295-308
29. Birtwistle, M.R., Hatakeyama, M., Yumoto, N., Ogunnaike, B.A., Hoek, J.B. and Kholodenko, B.N. (2007) Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol. Syst. Biol. 3, 144
30. Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., Pelle Della, P., Dias-Santagata, D., Hung, K.E. et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235
31. Gan, Y., Shi, C., Inge, L., Hibner, M., Balducci, J. and Huang, Y. (2010) Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29, 4947-4958
32. Douville, E. and Downward, J. (1997) EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene 15, 373-383
33. Shankaran, H. and Wiley, H.S. (2010) Oscillatory dynamics of the extracellular signal-regulated kinase pathway. Curr. Opin. Genet. Dev. 20, 650-655
34. Yu, C.F., Liu, Z.-X. and Cantley, L.G. (2002) ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J. Biol. Chem. 277, 19382-19388
35. Mirzoeva, O.K., Das, D., Heiser, L.M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N.J., Neve, R.M., Guan, Y. et al. (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565-572
36. Gopal, Y.N.V., Deng, W., Woodman, S.E., Komurov, K., Ram, P., Smith, P.D. and Davies, M.A. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 70, 8736-8747
37. Yoon, Y.-K., Kim, H.-P., Han, S.-W., Hur, H.-S., Oh, D.Y., Im, S.-A., Bang, Y.-J. and Kim, T.-Y. (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 8, 2526-2536
38. Stelniec-Klotz, I., Legewie, S., Tchernitsa, O., Witzel, F., Klinger, B., Sers, C., Herzel, H., Blüthgen, N. and Schäfer, R. (2012) Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol. Syst. Biol. 8, 601
39. Halilovic, E., She, Q.B., Ye, Q., Pagliarini, R., Sellers, W.R., Solit, D.B. and Rosen, N. (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 70, 6804-6814
40. Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T. and Bentires-Alj, M. (2012) JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22, 796-811
41. Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P.J.A., Ibrahim, Y.H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S. et al. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547-2557
42. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J. and Rosen, N. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71
43. Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M. et al. (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122
44. Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A. et al. (2014) Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra26
45. Nelander, S., Wang, W., Nilsson, B., She, Q.-B., Pratilas, C., Rosen, N., Gennemark, P. and Sander, C. (2008) Models from experiments: combinatorial drug perturbations of cancer cells. Mol. Syst. Biol. 4, 216
46. Molinelli, E.J., Korkut, A., Wang, W., Miller, M.L., Gauthier, N.P., Jing, X., Kaushik, P., He, Q., Mills, G., Solit, D.B. et al. (2013) Perturbation biology: inferring signaling networks in cellular systems. PLoS Comput. Biol. 9, e1003290
47. Miller, M.L., Molinelli, E.J., Nair, J.S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A.M., Singer, S. et al. (2013) Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci. Signal. 6, ra85